
|Articles|September 7, 2007
AMD eye drops trial kicks off
TareGen has initiated a multicentre Phase II clinical trial for the topically applied TG100801 in patients with age-related macular degeneration (AMD).
Advertisement
TareGen has initiated a multicentre Phase II clinical trial for the topically applied TG100801 in patients with age-related macular degeneration (AMD).
TG100801 is administered non-invasively as an eye drop and has been developed to suppress VEGF-mediated leakage and additional kinase targets associated with inflammation, oedema and angiogenesis.
A second topically applied compound for eye disease, TG100948, is also in early development.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
Why ST-100 is expanding from dry eye into corneal wound healing
2
Eichenbaum Acorns: Building the private academic model with Jeffrey S. Heier, MD
3
ONL Therapeutics completes enrollment in Phase 2 GALAXY trial for geographic atrophy
4
Water-soluble CBD eye drops lower IOP and dampen corneal sensitivity in glaucoma mouse model
5
















